Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France

About this trial

While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.

Eligibility criteria

Qualifiers

Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention

Subject affiliated to a social protection health insurance

Subject able to understand the objectives and risks of the research and to provide dated and signed consent

Subject who has been informed of the results of the preliminary medical examination

Disqualifiers

Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)

Very high bleeding risk defined by recent bleeding (<6 months) of type 3 of the BARC classification

Subject in an exclusion period (determined by a previous or ongoing study)

Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)

Trial design

Treatments tested in this trial

  • Administration of heparin after sheath insertion
  • Administration of heparin prior to sheath insertion

Treatment groups

550 Participants
are divided into 2 treatment groups